StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 12:32:48 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Jefferies finds AI drives up to 50% cost cuts in drug development http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST Jefferies finds AI drives up to 50% cost cuts in drug development http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST Jefferies finds AI drives up to 50% cost cuts in drug development http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST Jefferies finds AI drives up to 50% cost cuts in drug development http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST Jefferies finds AI drives up to 50% cost cuts in drug development http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST Jefferies finds AI drives up to 50% cost cuts in drug development http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST Jefferies finds AI drives up to 50% cost cuts in drug development http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST Jefferies finds AI drives up to 50% cost cuts in drug development http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST Jefferies finds AI drives up to 50% cost cuts in drug development http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST Jefferies finds AI drives up to 50% cost cuts in drug development http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST Jefferies finds AI drives up to 50% cost cuts in drug development http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST Jefferies finds AI drives up to 50% cost cuts in drug development http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST Jefferies finds AI drives up to 50% cost cuts in drug development http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST Jefferies finds AI drives up to 50% cost cuts in drug development http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST Travere Therapeutics (RTRX) Reports Complete Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis http://www.streetinsider.com/Corporate+News/Travere+Therapeutics+%28RTRX%29+Reports+Complete+Patient+Enrollment+in+Pivotal+Phase+3+DUPLEX+Study+of+Sparsentan+in+Focal+Segmental+Glomerulosclerosis/17662845.html si-local-file:///var/storage/newsbody/2020/1130/17662845.html http://www.streetinsider.com/Corporate+News/Travere+Therapeutics+%28RTRX%29+Reports+Complete+Patient+Enrollment+in+Pivotal+Phase+3+DUPLEX+Study+of+Sparsentan+in+Focal+Segmental+Glomerulosclerosis/17662845.html Mon, 30 Nov 2020 16:08:11 -0400 RTRX Travere Therapeutics (RTRX) Reports Complete Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis http://www.streetinsider.com/FDA/Travere+Therapeutics+%28RTRX%29+Reports+Complete+Patient+Enrollment+in+Pivotal+Phase+3+DUPLEX+Study+of+Sparsentan+in+Focal+Segmental+Glomerulosclerosis/17662845.html si-local-file:///var/storage/newsbody/2020/1130/17662845.html http://www.streetinsider.com/FDA/Travere+Therapeutics+%28RTRX%29+Reports+Complete+Patient+Enrollment+in+Pivotal+Phase+3+DUPLEX+Study+of+Sparsentan+in+Focal+Segmental+Glomerulosclerosis/17662845.html Mon, 30 Nov 2020 16:08:11 -0400 RTRX Travere Therapeutics (RTRX) Reports Complete Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis http://www.streetinsider.com/Management+Comments/Travere+Therapeutics+%28RTRX%29+Reports+Complete+Patient+Enrollment+in+Pivotal+Phase+3+DUPLEX+Study+of+Sparsentan+in+Focal+Segmental+Glomerulosclerosis/17662845.html si-local-file:///var/storage/newsbody/2020/1130/17662845.html http://www.streetinsider.com/Management+Comments/Travere+Therapeutics+%28RTRX%29+Reports+Complete+Patient+Enrollment+in+Pivotal+Phase+3+DUPLEX+Study+of+Sparsentan+in+Focal+Segmental+Glomerulosclerosis/17662845.html Mon, 30 Nov 2020 16:08:11 -0400 RTRX Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Announces+Completion+of+Patient+Enrollment+in+Pivotal+Phase+3+DUPLEX+Study+of+Sparsentan+in+Focal+Segmental+Glomerulosclerosis/17662788.html si-local-file:///var/storage/newsbody/2020/1130/17662788.html http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Announces+Completion+of+Patient+Enrollment+in+Pivotal+Phase+3+DUPLEX+Study+of+Sparsentan+in+Focal+Segmental+Glomerulosclerosis/17662788.html Mon, 30 Nov 2020 16:05:00 -0400 RTRX Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis http://www.streetinsider.com/Globe+Newswire/Travere+Therapeutics+Announces+Completion+of+Patient+Enrollment+in+Pivotal+Phase+3+DUPLEX+Study+of+Sparsentan+in+Focal+Segmental+Glomerulosclerosis/17662788.html si-local-file:///var/storage/newsbody/2020/1130/17662788.html http://www.streetinsider.com/Globe+Newswire/Travere+Therapeutics+Announces+Completion+of+Patient+Enrollment+in+Pivotal+Phase+3+DUPLEX+Study+of+Sparsentan+in+Focal+Segmental+Glomerulosclerosis/17662788.html Mon, 30 Nov 2020 16:05:00 -0400 RTRX Form 8-K Travere Therapeutics, For: Nov 12 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Travere+Therapeutics%2C+++++For%3A+Nov+12/17622142.html si-local-file:///var/storage/secattach/20201118/17622142.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Travere+Therapeutics%2C+++++For%3A+Nov+12/17622142.html Wed, 18 Nov 2020 17:18:00 -0400 RTRX Form 8-K/A Travere Therapeutics, For: Nov 12 http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Travere+Therapeutics%2C+++++For%3A+Nov+12/17622115.html si-local-file:///var/storage/secattach/20201118/17622115.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Travere+Therapeutics%2C+++++For%3A+Nov+12/17622115.html Wed, 18 Nov 2020 17:16:00 -0400 RTRX Form 4 Travere Therapeutics, For: Nov 16 Filed by: REED ELIZABETH E http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Travere+Therapeutics%2C+++++For%3A+Nov+16++Filed+by%3A+REED+ELIZABETH+E/17616952.html si-local-file:///var/storage/secattach/20201117/17616952.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Travere+Therapeutics%2C+++++For%3A+Nov+16++Filed+by%3A+REED+ELIZABETH+E/17616952.html Tue, 17 Nov 2020 21:00:00 -0400 RTRX Form 4 Travere Therapeutics, For: Nov 16 Filed by: Clague Laura http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Travere+Therapeutics%2C+++++For%3A+Nov+16++Filed+by%3A+Clague+Laura/17616953.html si-local-file:///var/storage/secattach/20201117/17616953.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Travere+Therapeutics%2C+++++For%3A+Nov+16++Filed+by%3A+Clague+Laura/17616953.html Tue, 17 Nov 2020 21:00:00 -0400 RTRX Form 4 Travere Therapeutics, For: Nov 16 Filed by: ROTE WILLIAM E. http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Travere+Therapeutics%2C+++++For%3A+Nov+16++Filed+by%3A+ROTE+WILLIAM+E./17616955.html si-local-file:///var/storage/secattach/20201117/17616955.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Travere+Therapeutics%2C+++++For%3A+Nov+16++Filed+by%3A+ROTE+WILLIAM+E./17616955.html Tue, 17 Nov 2020 21:00:00 -0400 RTRX Form 8-K Travere Therapeutics, For: Nov 13 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Travere+Therapeutics%2C+++++For%3A+Nov+13/17608291.html si-local-file:///var/storage/secattach/20201116/17608291.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Travere+Therapeutics%2C+++++For%3A+Nov+13/17608291.html Mon, 16 Nov 2020 16:05:00 -0400 RTRX